Hormone Receptor Expression in Meningiomas: A Systematic Review

Cancers (Basel). 2023 Feb 3;15(3):980. doi: 10.3390/cancers15030980.

Abstract

Meningiomas are, in most cases, low grade intracranial tumors. However, relapses are frequent. To date, only a few prognostic markers are described in the literature. Several studies have discussed the expression of progesterone, estrogen, androgen, and somatostatin receptors. The utility of analyzing these expressions for prognostic, theragnostic, and therapeutic purposes remains unclear. The aim of this study was to report the expression of these receptors, based on immunohistochemistry. Cochrane Collaboration guidelines and PRISMA statements were followed. We did an online search in PubMed using the MeSH database. References were selected if the investigations occurred from 1990 to 2022. 61 references were included (34 descriptive observational studies, 26 analytical observational studies, and one case report). In this review, we describe the expression of these receptors in function of age, sex, hormonal context, localization, histological subtype, grade, and recurrence.

Keywords: androgen; estrogen; hormone receptors; meningioma; progesterone; recurrence; somatostatin.

Publication types

  • Review

Grants and funding

This research received no external funding.